High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment
Authors' conclusion
Whilst frailty prevalence was highest in patients with adrenocortical hormone excess, even patients with NFA demonstrated an increased prevalence compared to the referent population. Future longitudinal studies are needed to evaluate the impact of various management strategies on frailty.
Study context
- Population
- Adults with adrenal disorders (NFA, MACS, CS, PA) and referent subjects without adrenal disorders, March 2019–August 2022520 adrenal, 89 referent
- Exposure
- Patients with adrenal disorders by hormonal subtype vs referent subjects without adrenal disorders
- Referentn = 89reference
- Outcome
- Prevalence of frailty (FI ≥ 0.25; FI = average score of 47 health variables)
Methodological detailsmulticentre, prospective enrolment
- Multicentre
- Prospective enrolment
Main finding
As reported in the abstract
Frailty prevalence, adjusted for age, sex and BMI
Each group vs referentOdds ratio (95% CI)
CS
19.2(6.7–70)
MACS
12.5(4.8–42.9)
PA
8.4(2.9–30.4)
NFA
4.5(1.7–15.9)
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Frailty prevalence by post-dexamethasone cortisolPost-dexamethasone cortisol 28-50 nmol/Lvs Referent | 4.6 (1.7–16.5) | |
| 0.050.21520Odds ratio (log scale) |
Frailty prevalence by post-dexamethasone cortisol
- Frailty prevalence similar to referent subjects when post-dexamethasone cortisol <28 nmol/L
Correlation of Frailty Index (FI) with physical function measures
- FI correlated with all measures of physical function
- P < 0.001
Original publication
High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment. Eur J Endocrinol. Published 17 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →